258 related articles for article (PubMed ID: 31619740)
21. Contribution of large genomic rearrangements in
Li N; Zethoven M; McInerny S; Healey E; DeSilva D; Devereux L; Scott RJ; James PA; Campbell IG
J Med Genet; 2023 Feb; 60(2):112-118. PubMed ID: 35396271
[TBL] [Abstract][Full Text] [Related]
22. Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families.
Pylkäs K; Erkko H; Nikkilä J; Sólyom S; Winqvist R
BMC Cancer; 2008 May; 8():146. PubMed ID: 18501021
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families.
Teo ZL; Park DJ; Provenzano E; Chatfield CA; Odefrey FA; Nguyen-Dumont T; ; Dowty JG; Hopper JL; Winship I; Goldgar DE; Southey MC
Breast Cancer Res; 2013 Feb; 15(1):R17. PubMed ID: 23448497
[TBL] [Abstract][Full Text] [Related]
24. A novel germline PALB2 deletion in Polish breast and ovarian cancer patients.
Dansonka-Mieszkowska A; Kluska A; Moes J; Dabrowska M; Nowakowska D; Niwinska A; Derlatka P; Cendrowski K; Kupryjanczyk J
BMC Med Genet; 2010 Feb; 11():20. PubMed ID: 20122277
[TBL] [Abstract][Full Text] [Related]
25. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
[TBL] [Abstract][Full Text] [Related]
26. Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy.
Ghiorzo P; Pensotti V; Fornarini G; Sciallero S; Battistuzzi L; Belli F; Bonelli L; Borgonovo G; Bruno W; Gozza A; Gargiulo S; Mastracci L; Nasti S; Palmieri G; Papadia F; Pastorino L; Russo A; Savarino V; Varesco L; Bernard L; Bianchi Scarrà G;
Fam Cancer; 2012 Mar; 11(1):41-7. PubMed ID: 21989927
[TBL] [Abstract][Full Text] [Related]
27. Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients.
Zhang Y; Wu H; Yu Z; Li L; Zhang J; Liang X; Huang Q
BMC Cancer; 2022 Aug; 22(1):842. PubMed ID: 35918668
[TBL] [Abstract][Full Text] [Related]
28. Cancer Risks Associated With Germline
Yang X; Leslie G; Doroszuk A; Schneider S; Allen J; Decker B; Dunning AM; Redman J; Scarth J; Plaskocinska I; Luccarini C; Shah M; Pooley K; Dorling L; Lee A; Adank MA; Adlard J; Aittomäki K; Andrulis IL; Ang P; Barwell J; Bernstein JL; Bobolis K; Borg Å; Blomqvist C; Claes KBM; Concannon P; Cuggia A; Culver JO; Damiola F; de Pauw A; Diez O; Dolinsky JS; Domchek SM; Engel C; Evans DG; Fostira F; Garber J; Golmard L; Goode EL; Gruber SB; Hahnen E; Hake C; Heikkinen T; Hurley JE; Janavicius R; Kleibl Z; Kleiblova P; Konstantopoulou I; Kvist A; Laduca H; Lee ASG; Lesueur F; Maher ER; Mannermaa A; Manoukian S; McFarland R; McKinnon W; Meindl A; Metcalfe K; Mohd Taib NA; Moilanen J; Nathanson KL; Neuhausen S; Ng PS; Nguyen-Dumont T; Nielsen SM; Obermair F; Offit K; Olopade OI; Ottini L; Penkert J; Pylkäs K; Radice P; Ramus SJ; Rudaitis V; Side L; Silva-Smith R; Silvestri V; Skytte AB; Slavin T; Soukupova J; Tondini C; Trainer AH; Unzeitig G; Usha L; van Overeem Hansen T; Whitworth J; Wood M; Yip CH; Yoon SY; Yussuf A; Zogopoulos G; Goldgar D; Hopper JL; Chenevix-Trench G; Pharoah P; George SHL; Balmaña J; Houdayer C; James P; El-Haffaf Z; Ehrencrona H; Janatova M; Peterlongo P; Nevanlinna H; Schmutzler R; Teo SH; Robson M; Pal T; Couch F; Weitzel JN; Elliott A; Southey M; Winqvist R; Easton DF; Foulkes WD; Antoniou AC; Tischkowitz M
J Clin Oncol; 2020 Mar; 38(7):674-685. PubMed ID: 31841383
[TBL] [Abstract][Full Text] [Related]
29. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
Riedlova P; Janoutova J; Hermanova B
Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
[TBL] [Abstract][Full Text] [Related]
30. Spectrum of PALB2 germline mutations and characteristics of PALB2-related breast cancer: Screening of 16,501 unselected patients with breast cancer and 5890 controls by next-generation sequencing.
Zhou J; Wang H; Fu F; Li Z; Feng Q; Wu W; Liu Y; Wang C; Chen Y
Cancer; 2020 Jul; 126(14):3202-3208. PubMed ID: 32339256
[TBL] [Abstract][Full Text] [Related]
31. A synonymous germline variant PALB2 c.18G>T (p.Gly6=) disrupts normal splicing in a family with pancreatic and breast cancers.
Yang C; Ceyhan-Birsoy O; Mandelker D; Jairam S; Catchings A; O'Reilly EM; Walsh MF; Zhang L
Breast Cancer Res Treat; 2019 Jan; 173(1):79-86. PubMed ID: 30255452
[TBL] [Abstract][Full Text] [Related]
32. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
33. Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.
Alter BP; Best AF
Breast Cancer Res Treat; 2020 Jul; 182(2):465-476. PubMed ID: 32488392
[TBL] [Abstract][Full Text] [Related]
34. Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample.
Yoshida R; Hagio T; Kaneyasu T; Gotoh O; Osako T; Tanaka N; Amino S; Yaguchi N; Nakashima E; Kitagawa D; Ueno T; Ohno S; Nakajima T; Nakamura S; Miki Y; Hirota T; Takahashi S; Matsuura M; Noda T; Mori S
Cancer Sci; 2021 Mar; 112(3):1310-1319. PubMed ID: 33421217
[TBL] [Abstract][Full Text] [Related]
35. Targeted massively parallel sequencing characterises the mutation spectrum of PALB2 in breast and ovarian cancer cases from Poland and Ukraine.
Myszka A; Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Kitsera N; Siekierzynska A; Southey MC
Fam Cancer; 2018 Jul; 17(3):345-349. PubMed ID: 29052111
[TBL] [Abstract][Full Text] [Related]
36. Alternative splicing and ACMG-AMP-2015-based classification of PALB2 genetic variants: an ENIGMA report.
Lopez-Perolio I; Leman R; Behar R; Lattimore V; Pearson JF; Castéra L; Martins A; Vaur D; Goardon N; Davy G; Garre P; García-Barberán V; Llovet P; Pérez-Segura P; Díaz-Rubio E; Caldés T; Hruska KS; Hsuan V; Wu S; Pesaran T; Karam R; Vallon-Christersson J; Borg A; ; Valenzuela-Palomo A; Velasco EA; Southey M; Vreeswijk MPG; Devilee P; Kvist A; Spurdle AB; Walker LC; Krieger S; de la Hoya M
J Med Genet; 2019 Jul; 56(7):453-460. PubMed ID: 30890586
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the need for routine clinical testing of PALB2 c.1592delT mutation in BRCA negative Northern Finnish breast cancer families.
Haanpää M; Pylkäs K; Moilanen JS; Winqvist R
BMC Med Genet; 2013 Aug; 14():82. PubMed ID: 23941127
[TBL] [Abstract][Full Text] [Related]
38. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
[TBL] [Abstract][Full Text] [Related]
39. A germline
Zhong Y; Schubert J; Wu J; Xu F; Lin F; Cao K; Zelley K; Luo M; Foster JB; Cole KA; MacFarland SP; Resnick AC; Storm PB; Li MM
Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32554798
[No Abstract] [Full Text] [Related]
40. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
Cragun D; Weidner A; Tezak A; Clouse K; Pal T
Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
